MGNX - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon.

We will begin the MacroGenics 2018 Second Quarter Corporate Progress and Financial Results Conference Call in just a moment. All participants are in a listen-only mode at the moment, and we will conduct a question-and-answer session at the conclusion of the call. At this point, I will turn the call over to Jim Karrels, Senior Vice President and Chief Financial Officer of MacroGenics.

Jim Karrels

Thank you, operator. to financial call operational welcome second discuss and XXXX quarter results. afternoon, MacroGenics' to conference our Good

For anyone this who Investors review announcements, our has is tab not had we which at a the on issued our press www.macrogenics.com. under release available afternoon website today's results, outlining the chance to

to from hours conference I You be days XX that archived this webcast listeners after call our of Act in completed. call alert two these is the can annual, like reports discussion forward-looking forward-looking those constitute future Securities also safe statements the listen of website, today's quarterly on would under provision for statements Litigation the as beginning purposes via statements a about prospects, to current the expectations, will of where the will that important approximately discussed results it SEC. Reform and Actual plans of those include result factors, including company's Private section our and materially with indicated for XXXX. various the by harbor differ factors risk filed may

views addition, of forward-looking In views should our not subsequent represent only any be any relied our representing as today, of date. upon as statements and as

the and turn elect like Scott Koenig, Chief update required to I'd may to specifically over disclaim views by forward-looking President do our now, some statements any call applicable And to so, at extent Executive in we to While to except MacroGenics' change, obligation the these law. point future, we the even Officer. Dr. if

Scott Koenig

you call welcome for via Thank and today. I'd Jim. Thank like conference to participating you, joining us. webcast everyone

and But focused back year. progress will that quarter I of fronts for do let call XXXX, financial several to I'm review first our financial candidate advanced me the to so, During the product is most Jim provide position. and the our our on and results an quarter turn made before happy we significant update on second who

Jim Karrels

Thank you, highlight for strong the Scott. we financial quarter, reported results second This afternoon, which our position.

enrolment had expenses due ended June June XX, primarily our research the Phase ended SOPHIA margetuximab described the This our X mainly to continued with As increase and MacroGenics for cancer XXXX. quarter XX and as million study for studies breast the clinical AML. the anti-PD-X XX, million was of release, cancer development to flotetuzumab trial combination two clinical for in in the XXXX the monotherapy as metastatic XX.X trial compared an well in in gastric quarter

administrative pattern quarter revenue, to due million as of ended as X.X services XX.X received we of million the activities. This in million related supply to as and their Corporation increased Revenue to Incyte two a headcount warrants to We general known to also purchase entered XX.X Bio shares also XXXX. XX, related XX, ERP enterprise which XX, with well $X.X clinical total MGAXXX, Provention into well compared stock. INCMGAXXXX common resource periods of and expenses. $X.X ended our payments of million for as development deferred X.X transactions of million million received of revenue as consisting XXXX. to recognition costs three million to related for XXXX XX, includes the June ended Revenue implementation previous from the three months system quarter XXXX expanded X.X from June revenue in during the as collaborative months received million the incurred planning for had of the ended collaborative three and June year. for of payments increased to agreements This June XX, We expenses from well recorded primarily total included or new manufacturing agreements of months for $XX.X increase was the XXXX. to manufacturing We support the our ended June compared primarily

a had June we XXXX, to XX, June XXXX. the XX, ended months net for of of net $XX.X loss three million a ended XX.X compared million quarter loss the For

we marketable securities out enable fund combined of of a assuming June our was XXXX to June our balance previously operations owed current activities. mentioned And programs cash with in of relates XX, our which our us equivalents I'll marketable Our balance anticipate XX, equivalents $XX.X to as at securities December Scott. cash, portion the as that collaborations Incyte compare collaboration contemplated. I'll turn MGAXXX that and should XXXX. And our accounts significant now, to the XX, payments an back XXX.X Based to call point believe currently XXXX million $XXX.X and to receivable of million us for on to operating cash cash, we mid-XXXX, and as million, amount from advance plan, receiving

Scott Koenig

Jim. you, Thank

As I multiple the program, make afternoon which to in opening, represents comments I continues focus mentioned the progress MacroGenics significant will across on fronts. this leading our value opportunities. near-term creation my most

optimized enhance Fc immune to has antibody, engineered with immune an and anti-HERX inate begin the me activation engagement Let system. which domain our novel of margetuximab,

in plus Our efficacy to study relapsed/refractory the evaluating breast SOPHIA trastuzumab compared pivotal XXX HERX-positive margetuximab chemotherapy approximately chemotherapy plus metastatic is of cancer patients.

ASCO with in from plus The junction anti-tumor with data cancer. gastroesophageal Annual chemotherapy-free we Pembrolizumab, the margetuximab for study and first patients to the presented to gastric a June, agent, few at in XXXX. position our line top in the study, in we X trial complete the may interim X of demonstrated this months enrollment and of anti-PD-X quarter patients to PFS we rate advanced which based In the expect cancer. accrued enhance in gastric to the presented activity of next ongoing have Meeting, announce We Phase data events, this that of Phase be combination results date on expect clinical

earlier patients. gastric we this enrolling year, the expansion may cancer recall that XX margetuximab the You by of additional gastric announced study

progress forward quarter additional of encouraged results in margetuximab complete to trial the announcing we in our with in the presenting expect we the first XXXX. anticipate first by and months look XXXX. few of we summary, We results quarter enrolment In the and next from are to

AML. of our is program myeloid acute next recognizes developed which both Our the monotherapy CDXXX molecule leukemia CDX, that and Flotetuzumab, treatment for is or being as DART

We have and the clinical in cohort completed present data of plan steps this we in and the updated Flotetuzumab to year. dose development announce later expansion next enrolment

rights Flotetuzumab Servier, and has Japan, North outside of partner, Korea development for commercialization America, Our and India.

and three will studies intention XXXX-XXXX worldwide to Under of And of while announced is In recall exclusive be licensed in according anticipated our cancer immune-oncology in with of You agreement, MacroGenics for XXXX. anti-PDX cohort microsatellite we in combination that terms is to Incyte anal with The merkel retains in instability-high the antibody. carcinoma this a and monotherapy to molecule the PDX-directed timeframe late their indications. of MGAXXX disclosures. pipeline develop year. are studies from that endometrial MGAXXX cancer at development MGAXXX their they has patients Incyte our open assays development pursue later Incyte will right this commercialization rights cell X June, in addition, to planning the these Phase in further expanded. Data the

that Incyte addition, a ongoing later provide meeting the In had study likely year. will this scientific an MacroGenics on monotherapy at initiated update MGAXXX

expressed range T that and them. MGDXXX provides I have programs molecules on on the PD-X will molecule to a potential administration a cells, X Phase malignancies. dose immune the LAG-X, and tumors schedule updates study brief is checkpoint hematological is and of DART end expect dose in being for by first-in-class well the as expansion currently evaluated solid establish year. we initiate MGDXXX cohorts as and of and MGDXXX the co-blockade We of in of a for two provide additional development treatment

target Another PD-X focused for MGDXXX designed both T is DART molecule on cells. and molecules, is co-blockade on end CTLA-X two of also year submitting We IND anticipate to immune the checkpoint by the MGDXXX, which XXXX. application

for creation BX-HX in XXXX to another franchise, shift me and value opportunity Let our beyond.

candidate, FC-optimized targets is Our antibody monoclonal Enoblituzumab advanced BX-HX. that most an

anti-PDX clinical and We with mAb Enoblituzumab enrolment quarter ongoing our expect present Enoblituzumab have of development the combination further completed provide the of study in of the and on fourth data guidance to XXXX. in in an

candidate Orlotamab types. multiple Phase DART tumor administration targeting as initiated in across the expansion in X franchise tumor is MGDXXX, being different cohorts and dose our evaluated a for in monotherapy known The dose previously recently BX-HX solid established We schedule Orlotamab second CDX. study is and Orlotamab, six a types. molecule BX-HX and clinical

started in patients. quarter first the is currently addition, that combination we accruing MGAXXX a study of In

The potent anti-tumor BX-HX shown that in franchise in activity our antibody drug candidate is has models. third conjugate MGCXXX, an preclinical anti-BX-HX

with We solid mention and molecules for tumors. a progress as have patients IND quickly initiating months with two MGCXXX development. clinical submitted an and the DART anticipating in I'll both Phase continued study Phase in additional in MGAXXX X combination to we that in coming X monotherapy

of in commenced MGDXXX molecule that recognizes gpAXX patients MGDXXX colorectal CDX. cancer. with is combination DART first a We MGAXXX with study The a recently and

contract infected commence of molecule X to developed a NIAID being third during cells expect quarter NIH. the the kill to we In addition, the under MGDXXX, at with of HIV study a DART phase XXXX

Finally, successful I'll building the corporate run. clinical GMT to commercial manufacturing and provide out our update. Rockville, a MacroGenics has we larger engineering headquarters and completed brief of in support build scale in suite a Maryland recently completed a

We this goal our major supports XXXX. milestone This a in development in have third in and biopharma is company. initiated facility of GMT integrated a our production fully becoming run the of quarter

another quarter can been as MacroGenics. you productive So see, and for has this busy

treatment our that to our excited efforts develop new to the questions any and be by for callers Operator? continuing progress have. now, address the we've innovative and be would cancer. may of And we glad to continue made therapies We look advance forward to program to

Operator

from The Instructions] Robinson Lawson Peter Humphrey. [Operator first question with SunTrust comes

Peter Lawson

view cancer, would line the XX On breast you Margetuximab top success that in what in as data? XQ

Scott Koenig

for approximately on at we're much as which These for endpoints a control designed is Obviously, in was and approximately individuals. approved. experimental very you arm Peter. primary had we set four HERX [indiscernible] control a for optimistically What the controls much the improvement recall, on based have of this expectation baseline, The our experienced as as as of X.X PFS is in And or and two was of OS. on historical the study trace PFS arm. sequential for we - Thank the was out months. you use a looking more population study of the testing base PFS months patients months read

for As the X.XX powered is follow successful, the XX%. we hazard XX%. PFS overall at ratio the survival and the you powered overall and on patients go this a out survival of then would and we was know, in with If set

Peter Lawson

what's How just do different you're have? sorry of three kind then Do the there? the on approaches out the plays and strategy think that HX differentiates think position BX-HX or a forward? And do where single you molecule a franchise, you the you move move one think there differentiation either to think just do what have enough you at getting and forwards is to you the there point, or you you

Scott Koenig

Thanks questions. for that

shown exploring into solid T conjugate explored expression engages this BX-HX the which well bispecific that CDX effort As of highly a to as an tumors kill over very target, get with given is the enhanced Preclinical expressed, that tumor studies put have cells tissues. that's mechanistically and you the normal antibody more targets know, we've a lot antibody, on as ADC. target we with well on

know, experience of we now with for in Enoblituzumab that plan As human types and the give well updating different further you in on where year, we'll tumor you earlier, in with don't preclinical that molecule. later guidance a development results studies. terms necessarily We've we Enoblituzumab, safety our as anti-PDX this efficacy four to combination predict long steps also models time that as point at had the at clinical also to the look call be as of very of we and that next Pembrolizumab,

filing monotherapy this was of this began begun will Second and six different as the expand it's that those tumor we is, MGDXXX. we lot heard molecule as this expect selected to MGCXXX combines heard, with MGDXXX monotherapy the effects by study for preclinical preclinical Orlotamab combination or Today, mechanistically, today, extremely of year tumors XXX effects dosed with even makes a as we have and we potent dosing. the supported and systems with and the we found announced model IND to as earlier with MGAXXX of eliminating and monotherapy enhance types Again, approximately for have anti-PDX into we patients you own of that just sense anti-PDX. single our Orlotamab at a data have that our for you next year,

we studies. or that combination think to all potentially inhibitors, will year opportunity we but more is molecules give data able lower either succeed of so an registration by to to molecules checkpoint to further next And be have will better a three guidance there which these advance with on to we

Operator

Thank next comes with The you. question from Evercore. Raffat Umer

Umer Raffat

seen, was on the I profile we rates. guess relates minute question efficacy I I really CRis at wanted should And CDXXX And including about we the and whether on I it be from think a may. be overall data durability ask dependent of between our was the CRs we've or and should read specifically, CRis we've to the focus because we should response aimed FDA for included or or the efficacy whether CR not And CRis. takes understanding if varying to when as not different on I CDXXX. is not partially

on low-teens XX% to how get this CR/CRi, CR up? rate, I and we it that close about looking was just drug? on color broader should So a had question sort a your of it follow to or Is think

Scott Koenig

question. that for So thank very you much

at data follow-up ASH year presented you our X ESMO patients on As year. we data last patients another XX on at the had first and last know, initial

to we've on to announced know, relapsed cells. we'll the you patients at year. those of as these refractory stem reduced patients the a specific question treatments call, regard chemotherapy undergone reserves a completed I that meeting and of marrow of expansion these part many XX very extensive in the patients enrolment many cohort, follow With later of have patients, and patients the this As large update scientific bone CRi, relapsed the in your importance regarding continue refractory this

variety, be it's even quite under leukemic normal precursor of can stem cells expand blood so circumstances, And be it controlled, cells the stem normal best reach to may so to completely and cells the if levels. the insufficient

for products would have for be a of XX,XXX course platelet a opportunity been here. to example, not a as a a look instance, case which based But obviously, durability approved you for With recovery we a will the but have CRHs considered into value, and enter as with case basis. that at some that So as reduce patient, predict well CRi achieves on on regard this, is FDA cannot success this. normal by know, the bleed will CR

that monotherapy will So only Flotetuzumab and again, we update soon cycle as guidance of study expect ASH, hope the single be - year on based with with of compelling outcome. previously, move a of you, we of showed regulation for to rationale, of MGAXXX, forward as we updated data, and to very initiate where later step, we Flotetuzumab next combination how PDLX will Flotetuzumab, may opportunity discuss that two single which of result molecule we looking we these this up at a combination we AML but our year some anti-PDX data molecules a as we last will both at on after blood, lot we a where in to also parameters we monotherapy better go the not on an see we noted course showed gives as the very have as

this the we point. how of is scene at view this So kind

Umer Raffat

Scott. some seeing And responses patient, on CR between offer type overall. CR helpful what of And that CRi true are really That's a patient? versus you our color differentiate perhaps of durability how patient you a can

Scott Koenig

ASH on in as were responses as maintenance patients last durable the long to this as and sustained. is months were their as therapy drug patient the six that posted can how So maintains also we long at their lot durability year, of further that the initial some also how we of be continued dictated durability long these the response. dictate by A and will seeing

meeting later at data We kind year. of will the this update this scientific

Operator

next question from Nomura/Instinet. comes Christopher Thank The you. with Marai

Jackson Harvey

it continuous just a question infusion Harvey gen for working next on bit I'm you're Christopher a infusion? Thank have if your if if doing Jackson elaborate be you. or if on Flotetuzumab. is path, could you're still believe another continuous registrational technology the on curious you I for Marai. and the This on little will you

Scott Koenig

kg, that worked dosing it recall, XX at regimen kg to the the nanograms per evaluated And patient. of schedule dosing with after on very a increased XXX as the much with weeks strategy days are and arrived then moving leading additional you forward on regimen the on and then kg three we Thank if of that's evaluation, benefits off on you XXX of or be minimize end dosing we infusion. start and depending that up the we to one as to then patients per X XXX had therapeutic maintain result per and as strategy X is will and put weeks would up we monotherapy. of they the nanograms four profile Flotetuzumab, as additional are regard we on three That of dose a for to your question. much, Jackson where nanograms continue cycles, anticipating favorable as a laboratory remaining dosing maximize it identifying days a With

have pointed regimens and SC out, We here. dosing in great a we'll different is molecule, this that With generation updating an enhances the as no combination a as creating success we dosing to other later that be have DART and we with half-life of next year. in had described regard [indiscernible] this molecule CDXXX with are exploring domain long-acting regimen MGAXXX we molecule

We the both effect short small or on cytokine tissue some a a molecules molecule. the that have in of as continuing with wings, cautious we acting without reduction such cells pattern a molecule and well normal molecule of incorporated acting should reduction elimination on that CDXXX dramatic do CDXXX any chosen have with - this both cells. such to based we're development on a the studies, as of earlier CDXXX the I are a advantage large The we've year expression small that in molecule. be and note preclinical be in may long the with We of data that CDX long molecule. presented acting some is observed alternative start

So able next maintenance that for we're to generation other patients may be molecule periods our drug in be may or longer where indications a type therapy along very time. for encouraged for MGDXXX with example, getting be of used,

Operator

next Nochomovitz Citigroup. Thank you. with Yigal The question comes from

Yigal Nochomovitz

study. missed have there? I Maybe still prostate was Do adjuvant the a comment I Enoblituzumab I new hear updates that didn't thought there study cancer you And also with ipilimumab? then underway? any a but this, on combo Is

Scott Koenig

passage the John that an an So study, Hopkins. This with at being conducted is IST not that. have we did today is to regard about study update

As you patients earlier to the the from was another in study recall, year, patients. initial the eight eight expanded enroll

call, very have you it, is so be I As commercial we to they enrolment had the given a Enoblituzumab we are regard at best the this a we ipilimumab, providing it that have my Enoblituzumab to but and a close year, completing enrolment was they expectation effects issues to that developing the standpoint, the early finished next an with not from should earlier out. were but combination that from update for that ipilimumab, stopped at understand had much we've not sometime did of results. noted CTLAX that competitive the not as that that in within getting meeting Not time. those for scientific heard recall company this study. we about regard ourselves a molecule standpoint, months on of an six and to study, And earnings With

small do I that of that of there we a to least in study one its number get believe but at continues drug combination. additional is patient that on enrolment, patients So continues the enrolled close

Jim Karrels

expanded XX study, on adjuvant the quick XX. from a Just to prostate patients clarification actually that's new

Yigal Nochomovitz

to of safety molecule, and regarding the understanding as pre-clinically of just the MGCXXX, the, obviously, at I of the you to ADC then least, linker warhead. have sense the a the wanted level And get

And reports the have you've human as molecule. the the As been with but understand ADC I those comfortable nonhuman to studies. unfortunate the Mersana as Daiichi ADCs, that ADC. I just with done I know, heading there work know of HERX of safety patient be like primates directed assume you deaths into some the to maybe nonetheless, well were

Jim Karrels

that for Yigal much very question. you Thank Yes.

are of excited the MGCXXX. about We prospects very

we technology in-licensed Synthon payload. As from you know, the with linker their linker/toxin

with may for some recall exact the had drug, molecule. you same toxicities a but As conducted some mice and Phase They study monkeys. an good my toxicity have has were with very From limiting or in we know, other at it's the five no recall, as as update we I to ASCO. actually in regard at nicely, data deaths studies understanding, the seen grade what X our a that which in associated is they to both of for presented molecules in have HERX dose ranges June started dose and the there directed the with or that from publicly technology that from linker not achieved meeting believe, not or Synthon intend introduce path is reported. specific, quite we Obviously, with have primates, a did studies. preclinical you've the the human toxicity

in So to start the seen humans. what study, with the studies we and see we the is mice obviously primate if have studies predict as

Yigal Nochomovitz

Okay. providing at point? And on just schedule are any the then XX, details more this you dosing

Scott Koenig

actually loads dose now. a we to done We're and that's There that. dose have We're weekly for I'm QX as higher a right drugs move have limiting and out then to where regimen right being other do happy we that. a dosing leading now. is conducted on

Operator

Cowen. The comes Peaker Thank with next Boris you. question from

Boris Peaker

statistical is happens of one and PFS hits the my in out? have SOPHIA how one So analysis another first trial, and significance sequential if I'm does that curious a endpoint OS, work not, since question does what you just

Scott Koenig

remarkable OS, patient, have readout OS see Well, significant to difference technically, still Clearly readout. still for of provides PFS, PFS, follow is the we data those that data present its in opportunities the don't we'll have what hit like. OS to the an if patients statistically we need looks a it for to relative we but to proceed for to the will quite if terms FDA, us have

Boris Peaker

year I'm of will good the what is ASH going a be at do how just we assuming And Flotetuzumab, get this at, and to consider I'm the data? to patients end many curious of you be data for

Scott Koenig

on What So the I'll plan good which let we was make least - you at was dose that our the conducted at or the more decision dataset data. my full what's XX present targeted patients. to

Operator

from question The next you. Chattopadhyay Wainwright. with Thank Debjit comes H.C.

Debjit Chattopadhyay

flotetuzumab, in evolved landscape in has inhibition checkpoint considerably has that obviously So it for over same and the development been time long a period.

given line some the what from how that the So line we in get treatment data over second months, we should that few given next and plan and you interpret starting data, even up, with evolution to guys you into do take plus with read Is a in forward. combo And Keytruda? MGDXXX, then follow front that something just a the up. Enoblituzumab program you're that study

Scott Koenig

totally So programs second are There I earlier, is and quick at independently targeting out Lilly opportunity pointed the as as and develop could different the to molecules combining other the looking these including with one that these other these Eli be looking BX-HX. molecules, the answer and were to independent molecules.

and ready we to Enoblituzumab combination. recall, in XXX. combination to combination the time, regard regard into because didn't that the looking the the So at go MGAXXX with as have with With are to answer that's pembrolizumab anti-PDX, we you clinic in with

And neck, lung, bladder to include a in head different four dataset types, which melanoma. wanted tumor so we and and get

well as experience - lung Within as head we cohorts, individuals. PDX and at the and neck both PDLX looking and unexperienced are both

forward. has the for with indication, other could present benefit the the development for So we are later therapeutic and we the regard as both and data to been Enoblituzumab think as dataset our based from to different of a with front this with going of internal both on fairly garnered as best course, obviously these Clearly, what has well we then indications, what that particular steps line therapies molecules have as current line large checkpoint other potentially plan therapies. have of molecule of set hear, experience the next in that you rate monotherapy will outline also our one this been response a we and experience populations and each

able this to will we So later update provide that. stay on be tuned, an year

Debjit Chattopadhyay

us you a on just that is And the construct? just to could antibody what drug drug follow-up MGDXXX, remind conjugate the ratio antibody the for Enoblituzumab,

Scott Koenig

on It's each the toxins X.X, antibody molecule.

Operator

Instructions] with Jonathan Partners. The Chang Leerink comes next from question [Operator

Unidentified Analyst

is a any discussion, for wondering This MGDXXX touched plan David [ph] which be that this looking but you on I for know what context there? might Jonathan. you indications was bit on on at Rusch we've on if could exploring. dialing I And in you provide

Scott Koenig

that. actually We've outlined

So this to with in approximately XX at head we're the and each bladder studies, prostate, the regard cell and mesothelioma, lung melanoma, testing cohort. looking cancer, monotherapy non-small for neck, monotherapy cancer, patients

So our expansion. we get at anti-PDX, when we're XX approximately looking patients the with combination the study NGALXX, to

depending mesothelioma, of change as we in on dose We are to still in the cell part towards study. we looking see renal sarcoma, escalation to what all non-small we're there the get that now high but get the cell closer, once we expansion, cancer, right we opportunity essentially earlier an comers prostate lung, and study, at Obviously, tumors. the have

Unidentified Analyst

quick any what to plan MGAXXX any endpoints on data. given With do monotherapy they insight one regarding insight and on you a data on present and question. they in more have - later you have this Just presenting year, indications the Incyte expect which to

Scott Koenig

well. initiated to in So, tuned. but intend say the we before transferred were as and the a patients molecule they are as describe as we studies we are pointed data at patients had and they new to that for that Incyte two registration the monotherapy efforts, you the expansion that can of to were data now, know, have expanding out, look XXX indication I described, R&D liberty proven are are over, pathway know over - indications part as additional and the expansion both given we not our that over combination, we but MSI their they we cohorts for the expanding the original stay

forward many So to for their expand and of combination they're intending studies going into molecules.

for would results. I stay the tuned say So

Operator

next the comes with Willey question from Stifel. And Stephen

Stephen Willey

little in data joined been if that look we're that along guess Phase is late, the presumably the we gastric consistent first bit and respect that bit of a I we've GI study, timing of you year. apologies decision where if a about you so the the perhaps reset? data with going are terms quarter maybe talk ASCO the swapping seen just response then little been essentially what be And getting and the to in cancer I be But lines of go curious the continues that at in the that Should trigger MGAXXX my asked. of forward to can just that to kind perhaps has progression a assume consequences this today what of the with a X might that arm with next for terms temporal program out of decision? a if same has just

Scott Koenig

couple We point to data. the the is that is you next cancer. this right sense pointed want plan along to also As in now. our and or early else. that, as looks Obviously, see good, My second pembrolizumab next something out, close that being out data additional know, or swapping front if therapy and enrolment sites this with months. out you MGAXXX consider to conducted out, therapy present using the getting in is line of enroll as for as we is things proceeded that to plan Should data HERX point gastric out study consider pathway I the obviously line as study We're whether you mature would call in in good that should in the a year to was place be positive full a molecule with - gastric expression. patients HERX earlier to XX registration be on

clear be decision tell of discussion, time we be. final data, by this a present pathway but very the I part the about will will to we can what come you is the haven't We internal that.

Operator

Debjit We with Chattopadhyay from question have a follow-up Wainwright. H.C.

Debjit Chattopadhyay

gastric because is in currently, the the for the But in efficacy enrolment the cancer data study, better versus primarily patients Asia Asian preliminary had, was obviously much Caucasian? data the

Scott Koenig

the you thank Debjit. So for question,

represents. in overall proportion and both of know patients is of terms higher Asia, in US gastroesophageal cancer in cancer you in patients that gastroesophageal gastric cancer, So as numbers and there higher of percentages cancer gastric proportion a and the that the a gastric cancer

both and still for right from would gastric patients, patients Europe. enrolling Asia clearly the enrolled but being the US is a are USX. there in that proportion now say cancer coming higher are in I We there

Debjit Chattopadhyay

I just in the of that last then conference on the But that your one as did MGDXXX, put in-house And program that you call. was bringing hear follow-up the PDLX? gpAXX, forward you're with again correctly backbone quick in combination

Scott Koenig

on for what was did to So safety as goal but sufficient dose to as the as drug further monotherapy, profile of that an the development monotherapy, a to acceptable we of not is our monotherapy and we, that clarification monotherapy. go this signal was believe just establish

so study. and and really [indiscernible] what are patients so initiated that's we And in that

if original anti-PDX. So combination study, we continuing forward, going the of are to with successful, the ultimately but the develop if still few patients the a be on, are monotherapy the will are continue on results that it follow we in to later combination

Debjit Chattopadhyay

or And a just pan-CRC based patients, not expression MSI this on study, gpAXX is right? MSS the and

Scott Koenig

Correct.

Operator

back call I'll closing session. question-and-answer now Koenig to Dr. remarks. the concludes the This turn you. Thank for

Scott Koenig

programs us to let like Have day. for know coming progress. you to our look you provide our the a joining months everyone know continuing we in that I'd good to and advance updates forward thank on again and

Operator

and the thank does for conclude today's great disconnect. may Ladies in have This participating all you Everyone, day. a program conference. you and gentlemen,

MacroGenics (MGNX) 7 Aug 182018 Q2 Earnings call transcript